These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12677268)

  • 1. Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.
    Wang P; Yi Q; Scully L; Heathcote J; Krahn M
    Can J Gastroenterol; 2003 Mar; 17(3):183-6. PubMed ID: 12677268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
    Veitsman E; Shahar E; Hassoun G; Lorber M; Kramskay R; Maor C; Pollack S; Baruch Y
    Harefuah; 2012 Dec; 151(12):684-7, 721, 720. PubMed ID: 23330260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
    Wei L; Li J; Yang X; Wang G; Feng B; Hou J; Duan Z; Jia J; Ren H; Niu J; Chen X; Wang FS; Shang J; Bo Q; Li R; Liu Y; Zhuang H
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1995-2003. PubMed ID: 27043040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
    Mangia A; Bányai T; De Bartolomeo G; Gervain J; Habersetzer F; Mulkay JP; Ouzan D; Parruti G; Passariello N; Remy AJ; Rizzetto M; Shiffman ML; Tice AD; Schmitz M; Tatsch F; Rodriguez-Torres M
    Liver Int; 2014 Aug; 34(7):e217-28. PubMed ID: 24251988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
    Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
    J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
    Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.
    Witkos M; Yi QL; Heathcote J; Kapral MK; Krahn MD
    Can J Gastroenterol; 2006 Feb; 20(2):107-11. PubMed ID: 16482237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
    Doffoël-Hantz V; Loustaud-Ratti V; Ramos-Casals M; Alain S; Bezanahary H; Liozon E; Fauchais AL; Vidal E
    Rev Med Interne; 2005 Feb; 26(2):88-94. PubMed ID: 15710254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.